14 January 2014 - Deborah Wilkes
Archived
Valeant Pharmaceuticals International aims to follow up its US$8.7 billion purchase of global eye health specialist Bausch + Lomb with "at least one significant deal" in 2014.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.